You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

May 14, 2021

New Draft Regulations on Medical Device Management in Vietnam

Subscribe to Updates

Since 2016, the government of Vietnam has issued a number of legal documents on medical device management, including Decree No. 36/2016/ND-CP dated May 15, 2016; Decree No. 169/ND-CP dated December 31, 2018; and Decree No. 03/2020/ND-CP dated January 1, 2020; all of which are concurrently valid. In an effort to unify and streamline regulations on the management of medical devices in Vietnam, the Ministry of Health (MOH) recently developed the draft of a new decree intended to replace the three decrees above. The draft is expected to be submitted to the government for further opinion and approval in the near future.

Below are some highlights of the new draft:

1. Clinical Trials of Medical Devices

The draft adds new regulations on clinical trials of medical devices. In particular, medical device trials will include three phases, in which phases 1 and 2 need to be finished before product registration while phase 3 will be conducted after the medical devices are approved for circulation following the specific requirement from the authorities. This regulation aims to continue evaluating the safety and efficacy of medical devices after they are widely used in the community in line with their usage conditions.

The draft also specifically stipulates cases (i) requiring full-stage clinical trials, (ii) being exempted from some stages of clinical trials, and (iii) being entirely exempted from clinical trials. The full exemption is intended to be applicable to class-A medical devices and medical devices that are already approved for circulation in at least one country in the world, and have sufficient safety and efficacy data.

Also, the draft sets out provisions on the requirements and obligations of relevant entities (the owners of the medical devices that need to be clinically evaluated and entities conducting the trials); dossiers for the trial; and procedures and processes to register and approve clinical trial protocols and trial results.

2. Medical Device Circulation

The draft adds two additional cases ((c) and (d) below) that qualify for the quick registration procedure. Accordingly, under the draft, the class-B/C/D medical devices that are subject to the quick registration procedure will include:

  • Products circulated in at least two of the following countries: Japan, Canada, Australia, the U.S., an EU member country, the U.K., or Switzerland.
  • Products circulated in Vietnam prior to December 31, 2020, and satisfying both of the following conditions:
    • The product was circulated for at least three years within a period of five years before the submission date.
    • There have been no warnings about the quality or safety of the product.
  • Products granted an import license and circulated in at least two countries in the world, one of which is Japan, Canada, Australia, the U.S., an EU member country, the U.K., or Switzerland.
  • Products meeting urgent needs for national defense, security, epidemic prevention and control, and overcoming of consequences of natural disasters and catastrophes, and having no substitutes available on the market.

Further, according to the draft, the MOH’s evaluation timeline will increase – up to 120 days instead of up to 60 days under current regulations. This is to ensure the feasibility of the evaluation.

3. Importation of Ingredients for Medical Device Production

Under the draft, import licenses are not required for medical device raw materials, except for materials containing narcotic substances and precursors.

4. Medical Device Advertisement

Under the draft, the content of medical device advertising must conform with either the dossiers for declaration of applicable standards for class-A medical devices, or the registration dossiers for class-B/C/D medical devices.

In addition, advertising contents will not require approval from the authorities. Instead, the holders of medical device registration numbers or their authorized entities will be responsible for publicly declaring the intended content and form of the advertising on the Medical Equipment Management Portal before conducting the advertising; the declaration for class-A/B medical devices would be applied from July 1, 2021 while the declaration for class-C/D medical devices would be applied from July 1, 2022.

5. Transitional Regulations

The draft sets out the transition mechanisms below:

  • Import licenses for class-B/C/D medical devices granted from 2018 to 2022 will be valid until December 31, 2022.
  • The procedures for obtaining import licenses during the transition period for class-B/C/D IVD medical devices, including reagents, calibrators, and control materials, are newly stipulated; this also means that the current procedures under Circular 47/2010/TT-BYT guiding the export and import of medicines and packaging in direct contact with medicines and Circular 30/2015/TT-BYT on import of medical equipment will be abolished.

 

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

June 24, 2024
Thailand’s Minister of Public Health recently promulgated the Ministerial Notification Re: Category 5 Narcotics Which Are Not Cannabis or Hemp Extract and Whose Consumption is Permitted for Treatment of Disease or for Research Purposes (2024). The notification took effect on April 23, 2024. The substances whose regulatory controls are affected by this new notification are psilocybin mushroom (Psilocybe cubensis (Earle) Singer), opium poppy (Papaver somniferum L. and Papaver bracteatum Lindl.), and other plants in these genera from which opium, opium alkaloids, psilocybin, or psilocin may be derived. As a result of this notification, these substances are now classified as category 5 narcotics that can be applied in medical treatment. Without the implementation of this notification, patients could not access newly developed medicines containing these substances, as Thailand’s Narcotic Code prohibits the possession and use of category 5 narcotics. Nonetheless, this does not mean that psilocybin mushrooms and opium can be used without any conditions. There is still a long process to go through before these substances can be used in medical treatment or clinical studies. Under the new notification, the FDA must first approve any medicinal drug formulation containing any of the above substances, and subsequently, the production must be approved for medical use or research purposes. The importation of medicinal drug formulations containing psilocybin mushrooms or opium is not allowed. This seemingly small regulatory change addresses the previous legal obstacle to the research and development of such medicines. According to the previous regulation, a physician or researcher could apply to the Thai FDA for a license to produce or possess medicines containing the aforementioned narcotics. However, production and consumption are considered different activities, and consuming a narcotic-containing medicine, even if it was produced under a valid license, is prohibited by the Narcotics Code and is punishable by imprisonment,
Read More
June 11, 2024
Advances in biotechnology have enabled the development of a range of new agricultural tools. From DNA sequencing to plant tissue culture and gene editing, these advances are facilitating the development of better crops. Genetically modified organisms (GMOs) are one well-known example of agricultural biotechnology. GMOs are organisms whose genetic material has been artificially altered by inserting a piece of foreign DNA. This DNA may be synthetic in origin or sourced from other organisms. Genome editing (also called gene editing or GEd) involves making precise changes to an organism’s genome without the integration of foreign DNA elements. Several approaches to genome editing have been developed. A well-known one is called CRISPR-Cas9, in which scientists make precise “cuts” in the DNA to create a new genetic variation. Unlike with GMOs, this introduces only minor modifications that are indistinguishable from natural mutations, typically by transplanting genes that code desirable traits from one species into another. GEd technology has been recognized and supported by the Food and Agriculture Organization of the United Nations (FAO). Thirteen FAO-member countries who are also members of the Organization for Economic Cooperation and Development (OECD) announced their support of the use of GEd technology for commercial uses and consumption at a recent WTO meeting. In addition, over 40 countries around the world, such as Argentina, Australia, Brazil, Canada, Chile, China, England, Japan, Kenya, the Philippines, Russia, the UK, and the US, have published policies emphasizing that foods free of transgenes (i.e., foods that do not contain genes transferred from external sources) are not GMOs, concluding that GEd plants are as safe as normal plants. In February 2024, the European Parliament approved new genomic techniques (NGTs), or GEd. As a result, plants that are produced using GEd technology are not classified by the EU as GMOs, and the EU
Read More
February 14, 2024
Thailand is preparing to implement new rules on drug importation for clinical studies. The Medicines Regulation Department of Thailand’s Food and Drug Administration (Thai FDA) first issued the Notification Re. Detailed Requirements for Drug Importation into Thailand for Clinical Studies almost a year ago, and the notification is expected to come into effect on March 1, 2024. Key Provisions The notification aims at enhancing the efficiency of conducting clinical studies while ensuring the protection of human subjects participating in such studies within Thailand. Some of its key provisions include: Definition of Clinical Study. The notification defines a “clinical study” as a study of a medicine involving human subjects, conducted to provide supporting evidence for the registration of a medicinal product in Thailand or other countries, including for additional indications or variations of a registration dossier. Compliance with ICH GCP. Clinical studies conducted in Thailand must adhere to the current edition of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) guidelines. Clinical Trial Application. Sponsors are required to submit a clinical trial application along with supporting documents to the Thai FDA for approval before commencing a clinical study. The permit remains valid for five years and is renewable. Supply of Investigational Drugs. Sponsors must obtain investigational drugs from manufacturers compliant with Good Manufacturing Practice (GMP) standards as recognized by the Thai FDA. Postapproval Obligations. The secretary-general of the Thai FDA may impose postapproval conditions or order investigators to conduct or suspend certain activities to ensure human subject protection and regulatory compliance. Regulatory Oversight. The Thai FDA is responsible for inspecting and overseeing the regulatory compliance of clinical studies, including during prestudy, ongoing, and poststudy phases. The Thai FDA may also conduct inspections of clinical studies conducted overseas. The Thai FDA
Read More
December 15, 2023
As part of its membership in Lex Mundi, Tilleke & Gibbins has published an updated edition of its Guide to Doing Business in Thailand for 2023. This guide outlines the key factors for starting and operating a business in the Thai market. Issues covered include: Investment incentives Financial facilities Exchange controls Import and export regulations Structures for doing business Requirements for the Establishment of a Business Operation of the Business Cessation or Termination of the Business Labor legislation, relations, and supply Tax Immigration requirements This publication is part of Lex Mundi’s Country Guides series prepared by member firms in more than 100 jurisdictions worldwide. The guides serve as a useful resource for planning international business strategy and researching new markets. The full Guide to Doing Business in Thailand is available through the button below.
Read More